582 related articles for article (PubMed ID: 18199773)
1. The potential for beta-structure in the repeat domain of tau protein determines aggregation, synaptic decay, neuronal loss, and coassembly with endogenous Tau in inducible mouse models of tauopathy.
Mocanu MM; Nissen A; Eckermann K; Khlistunova I; Biernat J; Drexler D; Petrova O; Schönig K; Bujard H; Mandelkow E; Zhou L; Rune G; Mandelkow EM
J Neurosci; 2008 Jan; 28(3):737-48. PubMed ID: 18199773
[TBL] [Abstract][Full Text] [Related]
2. 'Prion-like' propagation of mouse and human tau aggregates in an inducible mouse model of tauopathy.
Sydow A; Mandelkow EM
Neurodegener Dis; 2010; 7(1-3):28-31. PubMed ID: 20160454
[TBL] [Abstract][Full Text] [Related]
3. The beta-propensity of Tau determines aggregation and synaptic loss in inducible mouse models of tauopathy.
Eckermann K; Mocanu MM; Khlistunova I; Biernat J; Nissen A; Hofmann A; Schönig K; Bujard H; Haemisch A; Mandelkow E; Zhou L; Rune G; Mandelkow EM
J Biol Chem; 2007 Oct; 282(43):31755-65. PubMed ID: 17716969
[TBL] [Abstract][Full Text] [Related]
4. Regulatable transgenic mouse models of Alzheimer disease: onset, reversibility and spreading of Tau pathology.
Hochgräfe K; Sydow A; Mandelkow EM
FEBS J; 2013 Sep; 280(18):4371-81. PubMed ID: 23517246
[TBL] [Abstract][Full Text] [Related]
5. Cognitive defects are reversible in inducible mice expressing pro-aggregant full-length human Tau.
Van der Jeugd A; Hochgräfe K; Ahmed T; Decker JM; Sydow A; Hofmann A; Wu D; Messing L; Balschun D; D'Hooge R; Mandelkow EM
Acta Neuropathol; 2012 Jun; 123(6):787-805. PubMed ID: 22532069
[TBL] [Abstract][Full Text] [Related]
6. Inducible expression of Tau repeat domain in cell models of tauopathy: aggregation is toxic to cells but can be reversed by inhibitor drugs.
Khlistunova I; Biernat J; Wang Y; Pickhardt M; von Bergen M; Gazova Z; Mandelkow E; Mandelkow EM
J Biol Chem; 2006 Jan; 281(2):1205-14. PubMed ID: 16246844
[TBL] [Abstract][Full Text] [Related]
7. Tau-induced defects in synaptic plasticity, learning, and memory are reversible in transgenic mice after switching off the toxic Tau mutant.
Sydow A; Van der Jeugd A; Zheng F; Ahmed T; Balschun D; Petrova O; Drexler D; Zhou L; Rune G; Mandelkow E; D'Hooge R; Alzheimer C; Mandelkow EM
J Neurosci; 2011 Feb; 31(7):2511-25. PubMed ID: 21325519
[TBL] [Abstract][Full Text] [Related]
8. Novel human neuronal tau model exhibiting neurofibrillary tangles and transcellular propagation.
Reilly P; Winston CN; Baron KR; Trejo M; Rockenstein EM; Akers JC; Kfoury N; Diamond M; Masliah E; Rissman RA; Yuan SH
Neurobiol Dis; 2017 Oct; 106():222-234. PubMed ID: 28610892
[TBL] [Abstract][Full Text] [Related]
9. Neurofibrillary tangle formation by introducing wild-type human tau into APP transgenic mice.
Umeda T; Maekawa S; Kimura T; Takashima A; Tomiyama T; Mori H
Acta Neuropathol; 2014 May; 127(5):685-98. PubMed ID: 24531886
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of tau aggregation in cell models of tauopathy.
Khlistunova I; Pickhardt M; Biernat J; Wang Y; Mandelkow EM; Mandelkow E
Curr Alzheimer Res; 2007 Dec; 4(5):544-6. PubMed ID: 18220518
[TBL] [Abstract][Full Text] [Related]
11. A novel transgenic mouse expressing double mutant tau driven by its natural promoter exhibits tauopathy characteristics.
Rosenmann H; Grigoriadis N; Eldar-Levy H; Avital A; Rozenstein L; Touloumi O; Behar L; Ben-Hur T; Avraham Y; Berry E; Segal M; Ginzburg I; Abramsky O
Exp Neurol; 2008 Jul; 212(1):71-84. PubMed ID: 18490011
[TBL] [Abstract][Full Text] [Related]
12. Reversibility of Tau-related cognitive defects in a regulatable FTD mouse model.
Sydow A; Van der Jeugd A; Zheng F; Ahmed T; Balschun D; Petrova O; Drexler D; Zhou L; Rune G; Mandelkow E; D'Hooge R; Alzheimer C; Mandelkow EM
J Mol Neurosci; 2011 Nov; 45(3):432-7. PubMed ID: 21822709
[TBL] [Abstract][Full Text] [Related]
13. Age-dependent neurofibrillary tangle formation, neuron loss, and memory impairment in a mouse model of human tauopathy (P301L).
Ramsden M; Kotilinek L; Forster C; Paulson J; McGowan E; SantaCruz K; Guimaraes A; Yue M; Lewis J; Carlson G; Hutton M; Ashe KH
J Neurosci; 2005 Nov; 25(46):10637-47. PubMed ID: 16291936
[TBL] [Abstract][Full Text] [Related]
14. Generation of tau aggregates and clearance by autophagy in an inducible cell model of tauopathy.
Wang Y; Krüger U; Mandelkow E; Mandelkow EM
Neurodegener Dis; 2010; 7(1-3):103-7. PubMed ID: 20173337
[TBL] [Abstract][Full Text] [Related]
15. Tauopathies and tau oligomers.
Takashima A
J Alzheimers Dis; 2013; 37(3):565-8. PubMed ID: 23948895
[TBL] [Abstract][Full Text] [Related]
16. Cascade of tau toxicity in inducible hippocampal brain slices and prevention by aggregation inhibitors.
Messing L; Decker JM; Joseph M; Mandelkow E; Mandelkow EM
Neurobiol Aging; 2013 May; 34(5):1343-1354. PubMed ID: 23158765
[TBL] [Abstract][Full Text] [Related]
17. Tau Fibril Formation in Cultured Cells Compatible with a Mouse Model of Tauopathy.
Matsumoto G; Matsumoto K; Kimura T; Suhara T; Higuchi M; Sahara N; Mori N
Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29772786
[TBL] [Abstract][Full Text] [Related]
18. Potentiating tangle formation reduces acute toxicity of soluble tau species in the rat.
d'Orange M; Aurégan G; Cheramy D; Gaudin-Guérif M; Lieger S; Guillermier M; Stimmer L; Joséphine C; Hérard AS; Gaillard MC; Petit F; Kiessling MC; Schmitz C; Colin M; Buée L; Panayi F; Diguet E; Brouillet E; Hantraye P; Bemelmans AP; Cambon K
Brain; 2018 Feb; 141(2):535-549. PubMed ID: 29253129
[TBL] [Abstract][Full Text] [Related]
19. Early depletion of CA1 neurons and late neurodegeneration in a mouse tauopathy model.
Helboe L; Egebjerg J; Barkholt P; Volbracht C
Brain Res; 2017 Jun; 1665():22-35. PubMed ID: 28411086
[TBL] [Abstract][Full Text] [Related]
20. Accelerated human mutant tau aggregation by knocking out murine tau in a transgenic mouse model.
Ando K; Leroy K; Héraud C; Yilmaz Z; Authelet M; Suain V; De Decker R; Brion JP
Am J Pathol; 2011 Feb; 178(2):803-16. PubMed ID: 21281813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
